APO Research
Talk to an analyst

APO RESEARCH · REPORT

Coagulation Factor IX

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Coagulation Factor IX Market Outlook and Growth Opportunities 2026

20 December 2025191 pages

Choose your research edition.

Industry ResearchCoagulation Factor IX Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Coagulation Factor IX Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Coagulation Factor IX Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Coagulation Factor IX Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Coagulation Factor IX Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Coagulation Factor IX market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Coagulation Factor IX market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Coagulation Factor IX market include Takeda, Novo Nordisk, Pfizer, Baxter, Sanquin, Grifols, CSL Behring, Bioverativ and Aptevo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Coagulation Factor IX market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Coagulation Factor IX and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Coagulation Factor IX sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Coagulation Factor IX market size, projected growth trends, production technologies, key applications, and end-use industries.

Coagulation Factor IX Segment by Company

Takeda

Novo Nordisk

Pfizer

Baxter

Sanquin

Grifols

CSL Behring

Bioverativ

Aptevo

Coagulation Factor IX Segment by Type

Coagulation Factor IX (Plasma Derived)

Coagulation Factor IX (Recombinant)

Coagulation Factor IX Segment by Application

Adult

Kids

Coagulation Factor IX Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Coagulation Factor IX status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Coagulation Factor IX market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Coagulation Factor IX significant trends, drivers, influence factors in global and regions.

6. To analyze Coagulation Factor IX competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coagulation Factor IX market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Coagulation Factor IX and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coagulation Factor IX.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Coagulation Factor IX market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Coagulation Factor IX industry.

Chapter 3: Detailed analysis of Coagulation Factor IX manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Coagulation Factor IX in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Coagulation Factor IX in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Coagulation Factor IX Industry Trends Table 2. Coagulation Factor IX Industry Drivers Table 3. Coagulation Factor IX Industry Opportunities and Challenges Table 4. Coagulation Factor IX Industry Restraints Table 5. Global Coagulation Factor IX Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Coagulation Factor IX Revenue Share by Company (2021-2026) Table 7. Global Coagulation Factor IX Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Coagulation Factor IX Sales Volume Share by Company (2021-2026) Table 9. Global Coagulation Factor IX Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Coagulation Factor IX Company Ranking, (2024-2026) & (USD Million) Table 11. Global Coagulation Factor IX Key Company Manufacturing Base & Headquarters Table 12. Global Coagulation Factor IX Company, Product Type & Application Table 13. Global Coagulation Factor IX Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Coagulation Factor IX by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Coagulation Factor IX (Plasma Derived) Table 18. Significant Companies of Coagulation Factor IX (Recombinant) Table 19. Global Coagulation Factor IX Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Coagulation Factor IX Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Coagulation Factor IX Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Coagulation Factor IX Sales Volume Share by Type (2021-2026) Table 23. Global Coagulation Factor IX Sales Volume Share by Type (2027-2032) Table 24. Global Coagulation Factor IX Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Coagulation Factor IX Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Coagulation Factor IX Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Coagulation Factor IX Sales Value Share by Type (2021-2026) Table 28. Global Coagulation Factor IX Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Adult Table 30. Significant Companies of Kids Table 31. Global Coagulation Factor IX Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global Coagulation Factor IX Sales Volume by Application (2021-2026) & (W Units) Table 33. Global Coagulation Factor IX Sales Volume by Application (2027-2032) & (W Units) Table 34. Global Coagulation Factor IX Sales Volume Share by Application (2021-2026) Table 35. Global Coagulation Factor IX Sales Volume Share by Application (2027-2032) Table 36. Global Coagulation Factor IX Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Coagulation Factor IX Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Coagulation Factor IX Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Coagulation Factor IX Sales Value Share by Application (2021-2026) Table 40. Global Coagulation Factor IX Sales Value Share by Application (2027-2032) Table 41. Global Coagulation Factor IX Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global Coagulation Factor IX Sales by Region (2021-2026) & (W Units) Table 43. Global Coagulation Factor IX Sales Market Share by Region (2021-2026) Table 44. Global Coagulation Factor IX Sales by Region (2027-2032) & (W Units) Table 45. Global Coagulation Factor IX Sales Market Share by Region (2027-2032) Table 46. Global Coagulation Factor IX Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Coagulation Factor IX Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Coagulation Factor IX Sales Value Share by Region (2021-2026) Table 49. Global Coagulation Factor IX Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Coagulation Factor IX Sales Value Share by Region (2027-2032) Table 51. Global Coagulation Factor IX Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Coagulation Factor IX Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Coagulation Factor IX Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Global Coagulation Factor IX Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Coagulation Factor IX Sales by Country (2021-2026) & (W Units) Table 56. Global Coagulation Factor IX Sales Market Share by Country (2021-2026) Table 57. Global Coagulation Factor IX Sales by Country (2027-2032) & (W Units) Table 58. Global Coagulation Factor IX Sales Market Share by Country (2027-2032) Table 59. Global Coagulation Factor IX Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Coagulation Factor IX Sales Value Market Share by Country (2021-2026) Table 61. Global Coagulation Factor IX Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Coagulation Factor IX Sales Value Market Share by Country (2027-2032) Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Coagulation Factor IX Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Takeda Coagulation Factor IX Product Portfolio Table 67. Takeda Recent Development Table 68. Novo Nordisk Company Information Table 69. Novo Nordisk Business Overview Table 70. Novo Nordisk Coagulation Factor IX Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novo Nordisk Coagulation Factor IX Product Portfolio Table 72. Novo Nordisk Recent Development Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer Coagulation Factor IX Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Pfizer Coagulation Factor IX Product Portfolio Table 77. Pfizer Recent Development Table 78. Baxter Company Information Table 79. Baxter Business Overview Table 80. Baxter Coagulation Factor IX Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Baxter Coagulation Factor IX Product Portfolio Table 82. Baxter Recent Development Table 83. Sanquin Company Information Table 84. Sanquin Business Overview Table 85. Sanquin Coagulation Factor IX Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Sanquin Coagulation Factor IX Product Portfolio Table 87. Sanquin Recent Development Table 88. Grifols Company Information Table 89. Grifols Business Overview Table 90. Grifols Coagulation Factor IX Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Grifols Coagulation Factor IX Product Portfolio Table 92. Grifols Recent Development Table 93. CSL Behring Company Information Table 94. CSL Behring Business Overview Table 95. CSL Behring Coagulation Factor IX Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. CSL Behring Coagulation Factor IX Product Portfolio Table 97. CSL Behring Recent Development Table 98. Bioverativ Company Information Table 99. Bioverativ Business Overview Table 100. Bioverativ Coagulation Factor IX Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Bioverativ Coagulation Factor IX Product Portfolio Table 102. Bioverativ Recent Development Table 103. Aptevo Company Information Table 104. Aptevo Business Overview Table 105. Aptevo Coagulation Factor IX Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Aptevo Coagulation Factor IX Product Portfolio Table 107. Aptevo Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Coagulation Factor IX Distributors List Table 111. Coagulation Factor IX Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Coagulation Factor IX Product Image Figure 2. Global Coagulation Factor IX Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 4. Global Coagulation Factor IX Sales (2021-2032) & (W Units) Figure 5. Global Coagulation Factor IX Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Coagulation Factor IX Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Coagulation Factor IX (Plasma Derived) Image Figure 10. Coagulation Factor IX (Recombinant) Image Figure 11. Global Coagulation Factor IX Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Coagulation Factor IX Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Coagulation Factor IX Sales Volume Share by Type (2021-2032) Figure 14. Global Coagulation Factor IX Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Coagulation Factor IX Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Coagulation Factor IX Sales Value Share by Type (2021-2032) Figure 17. Adult Image Figure 18. Kids Image Figure 19. Global Coagulation Factor IX Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Coagulation Factor IX Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Coagulation Factor IX Sales Volume Share by Application (2021-2032) Figure 22. Global Coagulation Factor IX Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Coagulation Factor IX Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Coagulation Factor IX Sales Value Share by Application (2021-2032) Figure 25. Global Coagulation Factor IX Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 26. Global Coagulation Factor IX Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Coagulation Factor IX Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Coagulation Factor IX Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 30. North America Coagulation Factor IX Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Coagulation Factor IX Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Coagulation Factor IX Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 36. South America Coagulation Factor IX Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Coagulation Factor IX Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Coagulation Factor IX Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Coagulation Factor IX Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Coagulation Factor IX (Plasma Derived)
  • Coagulation Factor IX (Recombinant)
Applications
  • Adult
  • Kids
Companies covered
  • Takeda
  • Novo Nordisk
  • Pfizer
  • Baxter
  • Sanquin
  • Grifols
  • CSL Behring
  • Bioverativ
  • Aptevo

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Coagulation Factor IX Sales Value (2021-2032)
  4. 1.2.2 Global Coagulation Factor IX Sales Volume (2021-2032)
  5. 1.2.3 Global Coagulation Factor IX Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Coagulation Factor IX Market Dynamics
  1. 2.1 Coagulation Factor IX Industry Trends
  2. 2.2 Coagulation Factor IX Industry Drivers
  3. 2.3 Coagulation Factor IX Industry Opportunities and Challenges
  4. 2.4 Coagulation Factor IX Industry Restraints
3 Coagulation Factor IX Market by Company
  1. 3.1 Global Coagulation Factor IX Company Revenue Ranking in 2025
  2. 3.2 Global Coagulation Factor IX Revenue by Company (2021-2026)
  3. 3.3 Global Coagulation Factor IX Sales Volume by Company (2021-2026)
  4. 3.4 Global Coagulation Factor IX Average Price by Company (2021-2026)
  5. 3.5 Global Coagulation Factor IX Company Ranking (2024-2026)
  6. 3.6 Global Coagulation Factor IX Company Manufacturing Base and Headquarters
  7. 3.7 Global Coagulation Factor IX Company Product Type and Application
  8. 3.8 Global Coagulation Factor IX Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Coagulation Factor IX Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Coagulation Factor IX Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Coagulation Factor IX Market by Type
  1. 4.1 Coagulation Factor IX Type Introduction
  2. 4.1.1 Coagulation Factor IX (Plasma Derived)
  3. 4.1.2 Coagulation Factor IX (Recombinant)
  4. 4.2 Global Coagulation Factor IX Sales Volume by Type
  5. 4.2.1 Global Coagulation Factor IX Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Coagulation Factor IX Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Coagulation Factor IX Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Coagulation Factor IX Sales Value by Type
  9. 4.3.1 Global Coagulation Factor IX Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Coagulation Factor IX Sales Value by Type (2021-2032)
  11. 4.3.3 Global Coagulation Factor IX Sales Value Share by Type (2021-2032)
5 Coagulation Factor IX Market by Application
  1. 5.1 Coagulation Factor IX Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Kids
  4. 5.2 Global Coagulation Factor IX Sales Volume by Application
  5. 5.2.1 Global Coagulation Factor IX Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Coagulation Factor IX Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Coagulation Factor IX Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Coagulation Factor IX Sales Value by Application
  9. 5.3.1 Global Coagulation Factor IX Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Coagulation Factor IX Sales Value by Application (2021-2032)
  11. 5.3.3 Global Coagulation Factor IX Sales Value Share by Application (2021-2032)
6 Coagulation Factor IX Regional Sales and Value Analysis
  1. 6.1 Global Coagulation Factor IX Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Coagulation Factor IX Sales by Region (2021-2032)
  3. 6.2.1 Global Coagulation Factor IX Sales by Region: 2021-2026
  4. 6.2.2 Global Coagulation Factor IX Sales by Region (2027-2032)
  5. 6.3 Global Coagulation Factor IX Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Coagulation Factor IX Sales Value by Region (2021-2032)
  7. 6.4.1 Global Coagulation Factor IX Sales Value by Region: 2021-2026
  8. 6.4.2 Global Coagulation Factor IX Sales Value by Region (2027-2032)
  9. 6.5 Global Coagulation Factor IX Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Coagulation Factor IX Sales Value (2021-2032)
  12. 6.6.2 North America Coagulation Factor IX Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Coagulation Factor IX Sales Value (2021-2032)
  15. 6.7.2 Europe Coagulation Factor IX Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Coagulation Factor IX Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Coagulation Factor IX Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Coagulation Factor IX Sales Value (2021-2032)
  21. 6.9.2 South America Coagulation Factor IX Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Coagulation Factor IX Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Coagulation Factor IX Sales Value Share by Country, 2025 VS 2032
7 Coagulation Factor IX Country-level Sales and Value Analysis
  1. 7.1 Global Coagulation Factor IX Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Coagulation Factor IX Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Coagulation Factor IX Sales by Country (2021-2032)
  4. 7.3.1 Global Coagulation Factor IX Sales by Country (2021-2026)
  5. 7.3.2 Global Coagulation Factor IX Sales by Country (2027-2032)
  6. 7.4 Global Coagulation Factor IX Sales Value by Country (2021-2032)
  7. 7.4.1 Global Coagulation Factor IX Sales Value by Country (2021-2026)
  8. 7.4.2 Global Coagulation Factor IX Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Coagulation Factor IX Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Coagulation Factor IX Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Coagulation Factor IX Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Baxter
  20. 8.4.1 Baxter Company Information
  21. 8.4.2 Baxter Business Overview
  22. 8.4.3 Baxter Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Baxter Coagulation Factor IX Product Portfolio
  24. 8.4.5 Baxter Recent Developments
  25. 8.5 Sanquin
  26. 8.5.1 Sanquin Company Information
  27. 8.5.2 Sanquin Business Overview
  28. 8.5.3 Sanquin Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanquin Coagulation Factor IX Product Portfolio
  30. 8.5.5 Sanquin Recent Developments
  31. 8.6 Grifols
  32. 8.6.1 Grifols Company Information
  33. 8.6.2 Grifols Business Overview
  34. 8.6.3 Grifols Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Grifols Coagulation Factor IX Product Portfolio
  36. 8.6.5 Grifols Recent Developments
  37. 8.7 CSL Behring
  38. 8.7.1 CSL Behring Company Information
  39. 8.7.2 CSL Behring Business Overview
  40. 8.7.3 CSL Behring Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CSL Behring Coagulation Factor IX Product Portfolio
  42. 8.7.5 CSL Behring Recent Developments
  43. 8.8 Bioverativ
  44. 8.8.1 Bioverativ Company Information
  45. 8.8.2 Bioverativ Business Overview
  46. 8.8.3 Bioverativ Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bioverativ Coagulation Factor IX Product Portfolio
  48. 8.8.5 Bioverativ Recent Developments
  49. 8.9 Aptevo
  50. 8.9.1 Aptevo Company Information
  51. 8.9.2 Aptevo Business Overview
  52. 8.9.3 Aptevo Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Aptevo Coagulation Factor IX Product Portfolio
  54. 8.9.5 Aptevo Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Coagulation Factor IX Value Chain Analysis
  2. 9.1.1 Coagulation Factor IX Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Coagulation Factor IX Sales Mode & Process
  6. 9.2 Coagulation Factor IX Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Coagulation Factor IX Distributors
  9. 9.2.3 Coagulation Factor IX Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst